The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects.
Loche. S S; Cambiaso. P P; Carta. D D; Setzu. S S; Imbimbo. B P BP; Borrelli. P P; Pintor. C C; Cappa. M M
Key Findings
- Hexarelin (2 µg/kg IV) produces a rapid, robust GH surge in short normal and obese children, exceeding the response to GHRH.
- The GH response is similar across sex and pubertal stage, and testosterone priming further enhances it.
- No GH increase occurs in hypopituitary subjects, indicating the effect depends on an intact pituitary.
Practical Outcomes
- For biohackers interested in GH‑boosting, hexarelin shows that a very low IV dose can reliably raise GH without acute toxicity, suggesting it could be used in experimental protocols. However, the data are from children and require IV administration, so adult self‑experimentation would need careful dosing translation and medical supervision. The modest cortisol and prolactin spikes appear transient and likely not a major safety concern in short‑term use.
Summary
Hexarelin is a synthetic six‑amino‑acid peptide that, when given by IV at 2 µg per kilogram, triggers a strong, quick rise in growth hormone (GH) in normal and overweight children, but not in people who lack a functioning pituitary. The GH boost is bigger than that from standard GHRH, works in both boys and girls, and is even stronger after a short testosterone priming. No serious side effects were seen, though cortisol and prolactin rose a bit and then fell back to normal.
Abstract
Hexarelin (Hex) is a new synthetic hexapeptide with potent growth hormone (GH)-releasing activity in both animals and men. We evaluated the GH response to a maximal dose of Hex (2 micrograms/kg iv) and GH-releasing hormone (GHRH) (1-29, 1 microgram/kg iv) in 45 short normal children (24 males and 21 females, age 5.9-14 yr, 24 prepubertal and 21 in Tanner stage 2 or 3 of pubertal maturation), in 10 prepubertal obese children (7 males and 3 females, age 7.5-12 yr), and in 5 subjects with organic hypopituitarism (4 males and 1 female, age 8.4-21 yr). In 5 male subjects with constitutional growth delay (age 12.0-13.7 yr), the GH response to Hex was reevaluated 1 week after priming with testosterone enanthate (100 mg im). In all short normal children Hex caused a prompt and clear-cut increase of serum GH concentrations, with peaks occurring between 15-30 min from injection. The GH response to Hex was significantly higher than that observed after GHRH and was not different between males and females or between prepubertal and pubertal subjects. Priming with testosterone resulted in an increased GH response to Hex in all 5 subjects studied. No GH increase was observed in the hypopituitary subjects after either GHRH or Hex administration. In the obese children the GH responses to GHRH and to Hex were significantly lower than in the prepubertal children. Also, in the obese, the GH response to Hex was significantly higher than that observed after GHRH. In all short normal and obese children, but not in the hypopituitary subjects, Hex administration caused a slight but significant increase from baseline of both cortisol and PRL concentrations that returned to the baseline values within 2 h. None of the subjects experienced adverse side effects after Hex administration. This study shows that, in short normal and obese children, Hex is a potent GH-releasing stimulus with potential clinical utility.
Study Information
pubmed
1995
10.1210/jcem.80.2.7852535